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The regulation of expression of the c-S-adenosyl-l-methionine
(AdoMet) synthetase gene was investigated in T-cells during
G
!
}G
"
transition, as well as throughout the G
"
phase. Stimulation
of G
!
T-lymphocytes with concanavalin A induces AdoMet
synthetase gene expression, starting 8 h after stimulation. Inter-
leukin-2 (IL-2) stimulates the induction of this gene expression
and AdoMet synthetase activity in G
"
lymphoblasts, in part by
an increase in the transcription rate of the gene. Phorbol esters,
which also stimulate the proliferation of G
"
lymphoblasts, show
INTRODUCTION
S-Adenosyl-l-methionine (AdoMet) synthetase catalyses the
formation of AdoMet from methionine and ATP [1]. The
AdoMet synthetase gene is included in the 482 near-minimal set
of genes necessary for independent life [2], indicating that the
product of the reaction is essential for life. AdoMet is the methyl
donor in almost all transmethylation reactions [1]. A product of
these reactions is S-adenosyl-l-homocysteine (AdoHcy). The
hydrolysis of AdoHcy by AdoHcy hydrolase (EC 3.3.1.1), a
reversible enzyme, generates adenosine and homocysteine [3].
In mammalian tissues, three distinct forms of AdoMet syn-
thetase have been identified and designated as AdoMet syn-
thetases a, b and c, and all these forms have different biochemical
properties [4]. The a and b forms are expressed only in adult liver
[4,5]. On the other hand, the c form is widely distributed in
various tissues examined [4,6]. The c form in human lymphocytes
is composed of three polypeptide chains of 53, 51 and 38 kDa [7].
The 51 kDa protein appeared to be derived from the 53 kDa
protein [7]. We have cloned the catalytic 53}51 kDa protein
subunit cDNAs from rat [6] and human [8] kidney cDNA
libraries, and a human lymphocyte cDNA has also been cloned
recently [9].
Lymphocytes isolated from spleen or lymph nodes are in G
!
phase of the cell cycle [10]. Stimulation with the antigen-
presenting cell or with mitogenic lectins, like conconavalin A
(Con A), activates at least two signalling pathways involving an
elevation of cytosolic Ca#+ and diacylglycerol levels [11]. As a
consequence, quiescent T-lymphocytes enter the G
"
phase of the
cell cycle, where they produce interleukin-2 (IL-2), and high-
affinity receptors for this interleukin appear on the plasma
membrane [12]. Transition from G
"
to S phase occurs as a result
of IL-2 binding to its high-affinity receptor [13]. Phorbol esters,
are also able to induce G
"
lymphoblast entry into the S phase by
a different intracellular signalling pathway [14,15].
In this paper we demonstrate that the expression of the c
AdoMet synthetase gene and AdoMet synthetase activity are
Abbreviations used: Con A, concanavalin A; DEX, dexamethasone; GADPH, glyceraldehyde-phosphate dehydrogenase; IL-2, interleukin-2 ; PDBu,
phorbol 12,13-dibutyrate ; PKC, protein kinase C; AdoHcy, S-adenosyl-L-homocysteine; AdoMet, S-adenosyl-L-methionine.
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a similar kinetics of AdoMet synthetase mRNA induction. In
contrast, the mRNA levels of the S-adenosyl-l-homocysteine
hydrolase, another enzyme of the methionine cycle, remain
unchanged upon IL-2 or phorbol 12,13-dibutyrate treatment.
Dexamethasone and 8Br-cAMP, both inhibitors of lymphocyte
proliferation, are able to block the expression of the AdoMet
synthetase gene and, consequently, AdoMet synthetase activity.
Together these findings indicate that the AdoMet synthetase
gene is subject to cell-cycle regulation in T-lymphocytes
induced during T-lymphocyte activation as a consequence of the
interaction of IL-2 with its high-affinity receptors, while AdoHcy
hydrolase mRNA levels remain unchanged. The increase in
AdoMet synthetase gene expression is at least in part due to an
increase in the transcription rate of the gene. Phorbol esters also
stimulate c AdoMet synthetase gene expression and activity in
G
"
lymphoblasts. Finally, the effects of inhibitors of lymphocyte
activation on the expression of this gene have also been studied.
MATERIALS AND METHODS
Isolation of quiescent lymphocytes
Rat lymph nodes were aseptically removed and placed into
RPMI medium (Gibco) with 60 mg}ml gentamicin (Llorente)
and 0.25 mg}ml fungizone (Sigma). Lymphocytes were obtained
as in [14]. Briefly, filtered cells were pelleted, resuspended for
2 min in buffered 0.14 M ammonium chloride, pH 7.4, and
washed twice with RPMI supplemented with gentamicin, fungi-
zone and 2% (v}v) heat-inactivated fetal calf serum (Gibco). To
purify T-lymphocytes, nylon wool (Du Pont-New-England Nu-
clear) columns were used as described in [14]. Lymphocytes were
incubated at 37 °C in humidified 95% air}5% CO
#
for 1 h and
the non-adherent cells were used for stimulation.
Obtention of lymphoblasts and cell proliferation
Lymphoblasts were obtained by stimulation of spleen lympho-
cytes at a concentration of (5–7)¬10' cells}ml for 48 h with
2 lg}ml Con A (Aldrich) [16,17]. Cell proliferation assays were
performed as described in [14].
Northern blot analysis
Quiescent lymphocytes (1¬10)) were incubated with 2 lg}ml
Con A, 50 ng}ml phorbol 12,13-dibutyrate (PDBu; Sigma) or
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0.25 lM ionophore A 23187 ( Boehringer Mannheim). Lympho-
blasts (2¬10() were incubated with human recombinant IL-2
(20 units}ml; Hoffmann-La Roche Inc.), 1¬10−( M dexametha-
sone (DEX; Sigma) and}or 0.4 mM 8Br-cAMP (Boehringer
Mannheim). After stimulation, cells were grown at 37 °C in
humidified 95% air}5% CO
#
, and at different times cells were
washed with cold PBS and pelleted. Total cellular RNA was
isolated from cells by extraction in guanidinium thiocyanate as
described elsewhere [18]. Total RNA (20 lg) was electrophoresed
through a 2.2 M formaldehyde}1% agarose gel in 1¬ Mops
buffer (pH 7) and blotted onto a nylon membrane (Nytran, NY
13N; Renner GmbH). Filters were hybridized with either a
1.2 kb fragment of a rat c AdoMet synthetase cDNA clone [6] or
with a 1.9 kb fragment of a rat AdoHcy hydrolase cDNA clone
[3], labelled using the random primer technique (" 10*
c.p.m.}lg). The rat c AdoMet synthetase cDNA fragment does
not cross-hybridize with the other described synthetase mRNA
species (a}b), which are expressed only in hepatic tissue [4,5].
Blots were hybridized for 16 h at 42 °C in the presence of 50%
formamide}5¬SSC (0.15 M NaCl}0.015 M sodium citrate)}-
50 mM sodium phosphate (pH 6.5)}5¬ Denhardt’s solution
(0.02% Ficoll 400}0.02% polyvinylpyrrolidone}0.002% BSA),
washed twice at room temperature in the presence of
2¬SSC}0.1% SDS for 15 min, twice at 65 °C in the presence
of 2¬SSC}0.1%SDS for 15 min, twice at 65 °C in the presence of
1¬SSC}0.1% SDS for 30 min and, finally, two washes were
performed at 65 °C in the presence of 0.3¬SSC}0.1%SDS for
30 min. Membranes were exposed to X-ray film for 36 h at
®70 °C.
Measurement of AdoMet synthetase activity
Cells were stimulated with IL-2 or PDBu, as described above. At
different times, 20¬10' cells were pelleted, washed with PBS and
frozen at ®20 °C. Cells were homogenized by freezing and
thawing three times in 10 mM Tris}HCl, pH 7.5, 0.3 M sucrose,
0.1 mM EGTA, 1 mM benzamidine and 0.1% 2-mercapto-
ethanol and centrifuged in a microfuge at maximal speed for
15 min. AdoMet synthetase activity was measured, in the pres-
ence of 5 mM methionine, in the supernatant as described in [19].
Nuclear run-on transcription assay
Control or IL-2-stimulated lymphoblasts (2¬10( ; 5.5 h) were
washed twice with cold PBS and lysed with 1 ml of lysis buffer
[10 mM Tris}HCl (pH 7.4)}10 mM NaCl}3 mM MgCl
#
}0.5%
Nonidet P40}50 units}ml RNase inhibitor (Boehringer Mann-
heim)], incubated for 3 min on ice and then centrifuged at 1000 g
for 3 min. Nuclei were washed once with reaction buffer [20 mM
Tris}HCl (pH 8.0)}2.5 mM MgCl
#
}150 mM KCl}1 mM dithio-
threitol}20% (v}v) glycerol], resuspended in 100 ll of storage
buffer (2¬ reaction buffer plus 500 units}ml RNase inhibitor)
and frozen in liquid nitrogen. For the in itro transcription
reaction, nuclei were thawed on ice and incubated with 0.5 mM
ATP, CTP, GTP (Boehringer Mannheim), 2.4 mM creatine
phosphate (Sigma,), 0.02 mg}ml creatine kinase (Boehringer
Mannheim), 500 units}ml RNase inhibitor and 150 lCi of
[$#P]UTP (3000 Ci}mmol) (NEG. 007H, New England Nuclear)
in a total volume of 200 ll, for 45 min at 26 °C. Then, 5 ll of
50 mM CaCl
#
and 25 ll of 10 units}ml DNase (Boehringer
Mannheim) were added and incubated at 26 °C for another
30 min. The digest was incubated with 10 ll of 10 lg}ml pro-
teinase K in 600 ll of solution containing 200 mM Tris}HCl
(pH 7.4), 50 mM EDTA and 2% SDS for 30 min at 42 °C. A
10 ll aliquot of 10 mg}ml yeast tRNA (Boehringer Mannheim)
and 80 ll of 2 M sodium acetate, pH 5.2, were added, and
nuclearRNA was extractedwith 800 ll of water-saturated phenol
and 200 ll of chloroform}isoamyl alcohol (24:1). The aqueous
phase was precipitated with cold ethanol and the pellet was
washed with 75% ethanol. The pellet was then resuspended in
50 ll of 0.2 M NaOH, incubated on ice for 10 min and then
neutralized to pH 7.4 with 20 ml of 2.4 M Hepes free-acid. The
solution was applied to a Nick Column (Pharmacia LKB
Biotechnology Inc., Uppsala, Sweden) that had previously equili-
brated with RNase-free water. The radioactivity of the RNAs
transcribed in itro was determined, and equal amounts of
radioactive RNA from IL-2-stimulated or unstimulated cells
were used to hybridize with 5 lg of the plasmids: AdoHcy
hydrolase-pBluescript, c AdoMet synthetase-pUC118, glyceral-
dehyde-phosphate dehydrogenase (GADPH)-pGEM3Z, pBlue-
script, pUC118 and pGEM3Z, previously applied to a nylon
matrix (Nytran NY 13N; Renner GmbH) with the aid of a slot
blot apparatus. The nylon membranes containing the plasmids
were prehybridized for 4 h in prehybridization buffer containing
1 mg}ml yeast tRNA at 65 °C, followed by hybridization with
the $#P-labelled RNA for 72 h at 65 °C. The filters were washed
twice with 2¬ SSC for 30 min at 65 °C, once with 2.5 mg}ml of
RNase A and 5 units}ml of RNase T1 in 2¬ SSC for 30 min at
37 °C, and once with 2¬SSC at 25 °C for 15 min, and then
exposed to X-ray film for 3 days and quantified by computer-
assisted densitometry.
RESULTS
To determine whether c AdoMet synthetase gene expression
could be induced in resting T-lymphocytes in response to Con A,
a potent inducer of T-cell proliferation, we isolated total RNA at
different times after Con A-stimulation of lymph node T-cells,
and Northern blots were performed. When resting lymphocytes
were stimulated with this lectin, c AdoMet synthetase mRNA
levels started to increase as early as 8 h after stimulation, reached
maximum 16 h after stimulation, and stayed above basal levels as
late as 24 h after stimulation (Figure 1A). Activation of G
!
T-
lymphocytes by Con A leads to a simultaneous increase in both
intracellular Ca#+ and diacylglycerol. The possible involvement
of these intracellular messengers in AdoMet synthetase induction
was tested separately. As shown in Figure 1(C), treatment of
these cells with either PDBu, a phorbol ester that mimics
diacylglycerol by activating protein kinase C (PKC) or Ca#+
Figure 1 Induction of c AdoMet synthetase gene expression by Con A or
the Ca2+ ionophore A23187 and phorbol esters in T-lymphocytes
Quiescent T-lymphocytes were isolated and stimulated as described in the Materials and
methods section. (A) Northern blot analysis of total RNA (20 lg) isolated from lymph node
lymphocytes at the times (h) indicated after Con A (2 lg/ml) stimulation. (B) Methylene Blue
staining of the membranes after transfer. (C) Northern blot analysis of total RNA obtained from
quiescent lymphocytes after stimulation with PDBu (50 ng/ml) and/or Ca2+ ionophore A23187
(0.25 lM) for 20 h : C, control ; P, PDBu ; I, ionophore A23187.
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Figure 2 Time course of c AdoMet synthetase gene expression and AdoHcy hydrolase mRNA levels in G1 lymphoblasts after IL-2 or PDBu stimulation
Lymphoblasts were stimulated for different times (h), with IL-2 (20 units/ml) or PDBu (50 ng/ml). Northern blot analyses were performed using 20 lg of total RNA (A, B, D, E). (A) Lymphoblasts
stimulated with IL-2 and probed with AdoMet synthetase cDNA. (B) Lymphoblasts stimulated with IL-2 and probed with AdoHcy hydrolase cDNA. (D) Lymphoblasts stimulated with PDBu and
probed with AdoMet synthetase cDNA. (E) PDBu-stimulated lymphoblasts probed with AdoHcy hydrolase cDNA. (C and F) Methylene Blue staining of the membranes after transfer.
ionophore A23187 separately, did not induce expression of this
gene. However, both signals, Ca#+ increase and PKC stimulation,
were necessary to elicit a response (Figure 1C). Activation of
both signal-transduction pathways is needed for the appearance
of high-affinity IL-2 receptors on the T-cell plasma membrane
and for IL-2 secretion. About 5 h after Con A stimulation,
lymphocytes start to secrete IL-2 to the extracellular medium,
and IL-2 interacts with its high-affinity receptors [13]. All these
data suggest that IL-2 could regulate c AdoMet synthetase
mRNA levels.
To test this hypothesis, G
"
phase lymphoblasts were stimulated
with recombinant IL-2, and Northern blots were performed.
Addition of IL-2 to lymphoblasts obtained from rat spleen
induced an increase in the steady-state levels of c AdoMet
synthetase mRNA. The maximal increase, 5.3³0.5-fold (n¯ 3),
in c AdoMet synthetase mRNA levels could be detected 6 h after
IL-2 stimulation (Figure 2A), but c AdoMet synthetase mRNA
levels remained increased as late as 20 h after IL-2 stimulation,
when lymphoblasts were entering the S phase of the cell cycle, as
monitored by incorporation of radiolabelled thymidine into the
cells (results not shown). IL-2 stimulation of lymphoblasts did
not induce an increase in AdoHcy hydrolase mRNA levels
(Figure 2B).
Phorbol esters, like IL-2, are able to stimulate lymphoblast
proliferation. However, different signalling pathways have been
proposed for this proliferative effect [14,15] : IL-2 exerts its action
through a PKC-independent mechanism and phorbol esters
operate through PKC activation. Addition of PDBu (50 ng}ml)
induced an increase in c AdoMet synthetase mRNA levels. The
time course of c AdoMet synthetase gene expression was quite
similar to that observed with IL-2 (Figure 2D). The increase in
mRNA AdoMet synthetase levels after 6 h of PDBu stimulation,
compared with unstimulated levels, has been calculated to be
about 5.8³0.4-fold (n¯ 3). AdoHcy hydrolase mRNA levels
remained unchanged after PDBu activation of lymphoblasts
(Figure 2E).
To determine whether IL-2 or PDBu induction of c AdoMet
synthetase mRNA resulted in a concomitant increase in AdoMet
synthetase activity, this enzyme activity was measured at different
times after lymphoblast stimulation. As shown in Figure 3, an
increase of about 4-fold in AdoMet synthetase activity was
Figure 3 Time course of AdoMet synthetase activity in IL-2- or PDBu-
stimulated lymphoblasts
Lymphoblasts were stimulated for different times with 20 units/ml IL-2 (A), or with 50 ng/ml
PDBu (B). AdoMet synthetase activity was determined as indicated in the Materials and
methods section. The data show the means³S.D. of three different experiments performed in
triplicate.
observed after IL-2 or PDBu stimulation of lymphoblasts. The
highest value for AdoMet synthetase activity was observed about
8 h after lymphoblast stimulation, 2 h later than the observation
of maximal levels of c AdoMet synthetase mRNA. Maximal
AdoMet synthetase activity was still observed 12 h after PDBu
or IL-2 stimulation, when maximal levels of c AdoMet synthetase
mRNA levels were already decreasing.
An increase in the level of mRNA can be the result of increases
in the transcription rate of the gene and}or the half-life of the
messenger. Nuclear run-on assays were performed to determine
whether the effects of IL-2 on AdoMet synthetase expression in
T-lymphoblasts were related to increases in the rate of tran-
scription of this gene. Treatment of T-lymphoblasts with IL-2
was associated with a 3-fold increase in the rate of AdoMet
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Figure 4 Nuclear run-on analysis of the AdoMet synthetase and AdoHcy
hydrolase transcription rates after IL-2 treatment of rat lymphoblasts
The transcription run-on assay was performed with nuclei isolated from lymphocytes treated or
not for 5.5 h with IL-2. (A) Nylon matrices containing the indicated plasmids were hybridized
with the ‘ in vitro ’ transcribed RNAs. (B) The histogram shows the quantification of GADPH,
AdoHcy hydrolase and AdoMet synthetase transcription rates normalized to the corresponding
vectors. The transcription rates were calculated as the ratios of stimulated versus unstimulated
values. This panel shows the mean of two different experiments. C, control.
synthetase transcription (Figure 4). IL-2 treatment had no effect
on the transcription rate of the AdoHcy hydrolase gene or the
GADPH gene (Figure 4).
cAMP and DEX inhibit lymphoblast proliferation by different
signal-transduction pathways. To study a possible relationship
between T-cell proliferation and c AdoMet synthetase mRNA
levels, we next tested whether these inhibitors of lymphocyte
proliferation would affect IL-2-induced levels of c AdoMet
synthetase mRNA. Consequently, lymphoblasts pretreated for
30 min with DEX (10−( M) or 8Br-cAMP (0.4 mM) were stimu-
lated with IL-2 (20 units}ml) for 6 h. Figure 5A shows that both
drugs inhibited c AdoMet synthetase gene expression, although
8Br-cAMP did not completely inhibit the induction of this gene
by IL-2. As shown in Figure 5(C), in PDBu-stimulated lympho-
blasts, DEX, as well as 8Br-cAMP, completely abolished PDBu
induction of c AdoMet synthetase gene expression. Finally, we
decided to test the effects of the immunosuppressants on AdoMet
synthetase activity. As shown in Table 1, both 8Br-cAMP and
DEX inhibited IL-2- or PDBu-enhanced AdoMet synthetase
activity. Thus, both immunosuppressants concomitantly de-
creased c AdoMet synthetase mRNA levels, AdoMet synthetase
activity and cell proliferation, indicating that the induction of c
AdoMet synthetase mRNA levels, and thus AdoMet synthetase
activity, is closely related to lymphocyte proliferation.
DISCUSSION
This study demonstrates that IL-2 or PDBu treatment of G
"
-
phase T-lymphocytes results in up-regulation of c AdoMet
synthetase gene expression. The good correlation, both in the
kinetics and in the increases in c AdoMet synthetase mRNA
levels (5.3-fold) and AdoMet synthetase activity (4-fold), suggests
Figure 5 Regulation of AdoMet synthetase gene expression by 8Br-cAMP
and DEX in G1 lymphoblasts
Cells preincubated for 30 min with 8Br-cAMP (0.4 mM) or DEX (10−7 M) and stimulated with
IL-2 or PDBu for 6 h were harvested and total RNA was isolated. (A) Northern blot analysis
of lymphoblasts stimulated with IL-2 (20 units/ml) in the presence or absence of 8Br-cAMP or
DEX. (B) Methylene Blue staining of the membrane after transfer corresponding to (A) (upper)
and (C) (lower). (C) Northern blot analysis of lymphoblasts stimulated with PDBu (50 ng/ml)
in the presence or absence of 8Br-cAMP or DEX.
Table 1 Comparison of AdoMet synthetase mRNA levels, AdoMet syn-
thetase activity and cell proliferation in IL-2- and PDBu-stimulated
lymphoblasts preincubated with DEX or cAMP
Cells were treated as in Figure 5. Data are represented as the percentage of the values
corresponding to IL-2- or PDBu-stimulated cells subtracted from the values corresponding to
untreated cells. Cell proliferation was measured as indicated in the Materials and methods
section. The means³S.D. of three different experiments performed in triplicate are given.
AdoMet synthetase activity was measured in extracts of cells stimulated for 8 h, as described
in the Materials and methods section. The means³S.D. of three different experiments
performed in triplicate are given. For mRNA AdoMet synthetase analysis cells were harvested
after 6 h of stimulation. The means of two different experiments quantified by computer-assisted
densitometry are given.
­IL-2 ­PDBu
cAMP DEX cAMP DEX
Lymphoblast proliferation 44³5 2³0.5 0 0
AdoMet synthetase activity (%) 40³3 10³4 9³1 12³3
AdoMet synthetase mRNA levels (%) 32³5 9³1 11³2 27³2
that the increase in activity is due, at least in part, to an increase
in the mRNA levels. Nuclear run-on assays further demonstrated
that the induction of c AdoMet synthetase expression by IL-2 in
T-lymphoblasts is at least in part controlled by a transcriptional
mechanism. The half-life of the c AdoMet synthetase transcript
in IL-2- or PDBu-stimulated lymphoblasts is identical (about
4 h; results not shown), indicating that PDBu probably also
controls, as IL-2, the mRNA levels of c AdoMet synthetase, at
least partially, through a transcriptional mechanism.
The mRNA levels and the transcription rate of another enzyme
of the methionine cycle, AdoHcy hydrolase, remain unchanged
after IL-2 stimulation. These observations indicate that AdoMet
933c-S-Adenosyl-L-methionine synthetase in T-lymphocytes
synthetase could be one of the regulatory steps in the methionine
cycle.
8Br-cAMP and DEX have been described as inhibitors of
lymphocyte activation [20–23]. Little is known about the mol-
ecular events responsible for these alterations. Some genes are
induced as a consequence of DEX treatment in lymphocytes, but
expression of others is repressed [14,22–24]. The data shown in
Figure 5 and Table 1 indicate that c AdoMet synthetase mRNA
levels and activity are regulated by the two different immuno-
suppressants. We, and others, have shown that Raf-1 kinase is
necessary for IL-2- or phorbol ester-induced lymphoblast pro-
liferation [25,26]. Interestingly, cAMP inhibits Raf-1 kinase
activation [27]. On the other hand, activation of p70}85 S6
kinase in IL-2-responsive lymphoid cells is inhibited by cAMP
[28]. Further experiments have to be carried out to determine if
Raf-1 and}or p70}85 S6 kinases control c AdoMet synthetase
gene expression in rat lymphoblasts.
This report is the first evidence that c AdoMet synthetase gene
expression is controlled during the cell cycle. The a}b AdoMet
synthetase gene is selectively expressed only in liver [4,5], and, to
our knowledge, no regulation of the expression of the a}b
AdoMet synthetase gene has been described during the cell cycle.
In fact, a}b AdoMet synthetase mRNA could not be detected in
G
!
or G
"
phase T-lymphocytes after Con A or IL-2 stimulation.
(M. A. Pajares, L. Alvarez and R. Toben4 a, personal com-
munication). Our data indicate that the expression of the two
genes is differently regulated and that the expression of the c
AdoMet synthetase gene can be controlled by a proliferative
signal.
AdoMet is the methyl donor in almost all transmethylation
reactions [1]. A product of these reactions, AdoHcy, is hydrolysed
by AdoHcy hydrolase, generating adenosine and homocysteine
[3]. AdoMet is also a precursor of polyamines [29].
It has been shown that in proliferating T-lymphoblasts, levels
of AdoMet, AdoMet utilization and homocysteine are increased
compared with G
!
lymphocytes [30]. However, our results
demonstrate that the enzymes responsible for the generation of
AdoMet and the conversion of AdoHcy into homocysteine
exhibit differential regulation in IL-2-stimulated T-lymphoblasts :
c AdoMet synthetase transcription is increased while AdoHcy
hydrolase transcription remains unchanged. AdoHcy hydrolase
is a reversible enzyme [3] and is not a rate-limiting step in the
methionine cycle. Thus, an increase in AdoHcy levels due to
AdoMet utilization in transmethylation reactions could auto-
matically result in an increase in homocysteine levels. However,
post-translational modifications that could activate AdoHcy
hydrolase cannot be excluded.
An increase in the levels of polyamines has been described to
be essential for proliferation and differentiation in many cell
systems [29,31], including T-lymphocytes [32]. This increase in
the synthesis of polyamines requires a higher production of
AdoMet. In phytohaemagglutinin-stimulated lymphocytes the
levels of AdoMet are increased compared with G
!
lymphocytes
[30]. The level of transcripts for the key enzymes in polyamines
biosynthesis, AdoMet decarboxylase and ornithine decarboxy-
lase, are also increased after activation of lymphocytes with
mitogenic lectins [33,34]. Based on the results presented here, we
conclude that IL-2-triggered lymphocyte activation increases
AdoMet synthesis as a consequence of the increase in c AdoMet
Received 8 May 1996/19 June 1996 ; accepted 8 July 1996
synthetase transcript level. It would interesting to know whether
the regulation of c AdoMet synthetase gene expression by a
mitogenic signal is T-cell specific or is a general event, necessary
for the increase in polyamine levels during G
"
phase of the cell
cycle.
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